tbuckley/cabot-search huggingface dataset:
Chemical Studies on the Components of Normal and Neoplastic Tissues. I. Viscosity and Streaming Birefringence of Sodium Thymonucleate
Authors: Greenstein, Jesse P., Jenrette, Wendell V.
Journal: JNCI Journal of the National Cancer Institute (1940)

Journal Article Chemical Studies on the Components of Normal and Neoplastic Tissues. I. Viscosity and Streaming Birefringence of Sodium Thymonucleate Get access Jesse P. Greenstein, Jesse P. Greenstein research fellow National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Wendell V. Jenrette Wendell V. Jenrette technical assistance National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 1, Issue 1, 1940-1941, Pages 77–90, https://doi.org/10.1093/jnci/1.1.77 Published: 01 August 1940
596TiP Phase I first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumours
Authors: J. Powderly, T. Shimizu, P. Lorusso, A. Razak, K.D. Miller, A.V. Balar, J. Bruix, L.S. Michel, M. Blaney, X. Guan, S. Lacy, S. Lally, S. Lambert, R. Leibman, G. Vosganian, T. Golan, A. Tolcher
Journal: Annals of Oncology (2020)

Glycoprotein-A repetitions predominant (GARP) regulates membrane-bound transforming growth factor β1 (TGFβ1), an immunosuppressive cytokine. ABBV-151 is a first-in-class monoclonal antibody (mAb) that binds to the GARP-TGFβ1 complex and blocks TGFβ1 release. Preclinical data demonstrated that targeting both GARP-TGFβ1 and programmed cell death protein 1 (PD-1) improved antitumor effects compared with anti–PD-1 alone. Combining ABBV-151 with the anti–PD-1 mAb budigalimab (ABBV-181) may enable a more effective antitumor immune response by reducing the immunosuppressive effect of TGFβ1. This is a multicenter phase I, dose escalation and dose expansion study (NCT03821935) in patients (pts; ≥18 yr, Eastern Cooperative Oncology Group performance status 0–1) with locally advanced or metastatic solid tumors. The primary objective of dose escalation is to determine the recommended phase II dose (RP2D) of ABBV-151 as monotherapy or with budigalimab; dose expansion will assess the objective response rate of ABBV-151 ± budigalimab. Secondary/exploratory objectives include assessing preliminary efficacy, safety, tolerability, pharmacokinetics (PK), and evaluating potential pharmacodynamic and predictive biomarkers. Dose escalation of ABBV-151, guided by a Bayesian optimal interval design, will assess dose-limiting toxicities during the first 28-day cycle and will be utilized until the RP2D is defined. ABBV-151 + budigalimab (fixed dose) will start ≥2 dose levels below that proven safe for ABBV-151. Adverse events will be evaluated per National Cancer Institute Common Terminology Criteria v5.0. Response will be assessed using Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 and iRECIST every 8 weeks. PK of ABBV-151 will be characterized. Saturation of GARP-TGFβ1 on platelets and PD-1 on CD4 T cells will be determined. Modulation of cytokines, chemokines, lymphocyte activity, and gene expression will be assessed in blood, while gene signatures and protein markers will be explored in tumor tissues. Baseline tumor characteristics will be retrospectively related to response. Enrollment initiated Mar 2019, with 37 pts enrolled as of May 2020. NCT03821935. Medical writing support was provided by Judith Land, PhD, from Aptitude Health, The Hague, the Netherlands, and funded by AbbVie. AbbVie. AbbVie Inc.
Oligoprogressive Disease With SCLC Transformation in EGFR-Mutated NSCLC: How Biology Knowledge Can Change the Game Rules
Authors: Daniele Pignataro, Valentina Bertaglia, Paolo Bironzo, Emanuela Olmetto, Chiara Pisano, Valerio Maria Napoli, Cristina Mantovani, Luisella Righi, Silvia Novello
Journal: Journal of Thoracic Oncology (2020)
Early Cholangiocarcinoma Detection With Magnetic Resonance Imaging Versus Ultrasound in Primary Sclerosing Cholangitis
Authors: John E. Eaton, Christopher L. Welle, Zeinab Bakhshi, Shannon P. Sheedy, Ilkay S. Idilman, Gregory J. Gores, Charles B. Rosen, Julie K. Heimbach, Timucin Taner, Denise M. Harnois, Keith D. Lindor, Nicholas F. LaRusso, Andrea A. Gossard, Konstantinos N. Lazaridis, Sudhakar K. Venkatesh
Journal: Hepatology (2020)

Early detection of perihilar cholangiocarcinoma (CCA) among patients with primary sclerosing cholangitis (PSC) is important to identify more people eligible for curative therapy. While many recommend CCA screening, there are divergent opinions and limited data regarding the use of ultrasound or magnetic resonance imaging (MRI) for early CCA detection, and it is unknown whether there is benefit in testing asymptomatic individuals. Our aims were to assess the diagnostic performances and prognostic implications of ultrasound and MRI-based CCA detection.This is a multicenter review of 266 adults with PSC (CCA, n = 120) who underwent both an ultrasound and MRI within 3 months. Images were re-examined by radiologists who were blinded to the clinical information. Respectively, MRI had a higher area under the curve compared with ultrasound for CCA detection: 0.87 versus 0.70 for the entire cohort; 0.81 versus 0.59 for asymptomatic individuals; and 0.88 versus 0.71 for those listed for CCA transplant protocol. The absence of symptoms at CCA diagnosis was associated with improved 5-year outcomes including overall survival (82% vs. 46%, log-rank P < 0.01) and recurrence-free survival following liver transplant (89% vs. 65%, log-rank P = 0.04). Among those with asymptomatic CCA, MRI detection (compared with ultrasound) was associated with reduction in both mortality (hazard ratio, 0.10; 95% confidence interval, 0.01-0.96) and CCA progression after transplant listing (hazard ratio, 0.10; 95% confidence interval, 0.01-0.90). These benefits continued among patients who had annual monitoring and PSC for more than 1 year before CCA was diagnosed.MRI is superior to ultrasound for the detection of early-stage CCA in patients with PSC. Identification of CCA before the onset of symptoms with MRI is associated with improved outcomes.
1217P Breathomics eNose technology as a non-invasive, inexpensive, point-of-care predictive test to detect early stage lung cancer in never or former light smokers
Authors: S. Schmid, S. Schouwenburg, E. Stewart, A.F. Fares, P. Bradbury, F. Shepherd, N. Leighl, A. Sacher, D. Patel, X. Li, W. Xu, G. Liu
Journal: Annals of Oncology (2020)
The Exclusion of Older Persons From Vaccine and Treatment Trials for Coronavirus Disease 2019—Missing the Target
Authors: Benjamin K. I. Helfand, Margaret Webb, Sarah L. Gartaganis, Lily Fuller, Churl-Su Kwon, Sharon K. Inouye
Journal: JAMA Internal Medicine (2020)

This cross-sectional study evaluates the risk of exclusion for older adults in randomized clinical trials for treatment and vaccine interventions in coronavirus disease 2019.
841P Phase II study of anlotinib plus pemetrexed for platinum-resistant epithelial ovarian cancer
Authors: J. Chen, W. Wei, L. Zheng, H. Li, Y. Feng, T. Wan, J. Qiu, X. Jiang, Y. Xiong, J. Li, H. Huang, L. Song, J. Liu, Y. Zhang
Journal: Annals of Oncology (2020)
946P Germinal immunogenetics and response to nivolumab in recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC) patients (pts): TopNIVO ancillary study
Authors: E.B. Saada, Y. Koudou, A. Daste, J. Fayette, G. Lefebvre, S. Zanetta, C. Toullec, D. Cupissol, S. Salas, M-C. Kaminsky-Forrett, A.C. Johnson, E. Vauleon, N. Ebran, M. Schmidt, M. Texier, F. Peyrade, G. Milano, J. Guigay, C. Even, M-C. Etienne-Grimaldi
Journal: Annals of Oncology (2020)
306P Real-life management and prognosis of young women (≤ 40 yo) with de novo metastatic breast cancer in the multicenter national observational ESME program
Authors: A. Francois, A. Lusque, C. Levy, B. Pistilli, E. Brain, D. Pasquier, M. Debled, J.C. Thery, A. Gonçalves, I. Desmoulins, T. de La Motte Rouge, C. Faure, J-M. Ferrero, J-C. Eymard, M.A. Mouret Reynier, T. Petit, O. Payen, L. Uwer, S. Guiu, J-S. Frenel
Journal: Annals of Oncology (2020)
腫よう免疫におけるインターフェロン-γ(IFN-γ)の役割 IFN-γ欠損マウスでは腫よう除去能を持つT細胞は生成されるが、腫よう部位へ移動出来ない
Authors: Nakajima C, Uekusa Y, Iwasaki M, Yamaguchi N, Mukai T, Gao P, Tomura M, Ono S, Hamaoka T
Journal: Cancer Research (2001)
LBA9_PR Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study
Authors: R.J. Kelly, J.A. Ajani, J. Kuzdzal, T. Zander, E. Van Cutsem, G. Piessen, G. Mendez, J.L. Feliciano, S. Motoyama, A. Lièvre, H. Uronis, E. Elimova, C. Grootscholten, K. Geboes, J. Zhang, L. Zhu, M. Lei, K. Kondo, J.M. Cleary, M. Moehler
Journal: Annals of Oncology (2020)
281MO Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database
Authors: M. Carausu, M. Carton, L. Cabel, A. Patsouris, C. Levy, B. Verret, A. Mailliez, M. Debled, A. Gonçalves, I. Desmoulins, I. Lecouillard, T. Bachelot, J-M. Ferrero, J-C. Eymard, M-A. Mouret-Reynier, M. Chevrot, E. Pons-Tostivint, L. Uwer, A. Darlix, L. Bozec Le Moal
Journal: Annals of Oncology (2020)
1782MO Health-related quality of life (HRQoL) in KEYNOTE-604: Pembrolizumab (pembro) or placebo added to etoposide and platinum (EP) as first-line therapy for ES-SCLC
Authors: H.R. Kim, M.M. Awad, A. Navarro, M. Gottfried, S. Peters, T. Csőszi, P.K. Cheema, D. Rodriguez-Abreu, M. Wollner, J.C-H. Yang, J. Mazieres, F.J. Orlandi, A. Luft, M. Gümüş, T. Kato, G.P. Kalemkerian, Y. Luo, M.L. Santorelli, M.C. Pietanza, C.M. Rudin
Journal: Annals of Oncology (2020)
Medicaid Expansion and Surgical Care—Evaluating the Evidence
Authors: John W. Scott, John Z. Ayanian, Justin B. Dimick
Journal: JAMA Surgery (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Corrigendum to “Advanced multimodal nanoparticles delay tumor progression withclinical radiation therapy” [Journal of Controlled Release 238 (2016) 103–133]
Authors: Alexandre Detappe, Sijumon Kunjachan, Lucie Sancey, Vincent Motto-Ros, Douglas Biancur, Pascal Drane, Romain Guieze, G. Mike Makrigiorgos, Olivier Tillement, Robert Langer, Ross Berbeco
Journal: Journal of Controlled Release (2020)
862P Prognostic role of CD3, CD4, CD8 and FOXP3 positive populations in early-stage endometrial carcinoma
Authors: V. Heredia Soto, T. Pellinen, R. Turkki, J.L. Ramón Patiño, I. Ruz-Caracuel, L.E. García de la Calle, Á. López Janeiro, F.J. Escudero, M. Miguel, R. Crespo, P. Ruiz, A. Peláez-García, D. Hardisson, A. Redondo, M. Mendiola
Journal: Annals of Oncology (2020)
659P Rucaparib population pharmacokinetics (PPK) and exposure-response (ER) analyses in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in TRITON2
Authors: S. Chowdhury, A. Patnaik, D. Campbell, J. Shapiro, A.H. Bryce, R. McDermott, B. Sautois, N.J. Vogelzang, R. Bambury, E. Voog, J. Zhang, M. Green, J. Beltman, D. Despain, A.D. Simmons, S.P. Watkins, A. Golsorkhi, J. Xiao, W. Abida
Journal: Annals of Oncology (2020)
‘COVID-19 lockdown: A protective measure or exacerbator of health inequalities? A comparison between the United Kingdom and India.’ a commentary on “the socio-economic implications of the coronavirus and COVID-19 pandemic: A review”
Authors: Shaheen Sardar, Iqra Abdul-Khaliq, Aysha Ingar, Hanaa Amaidia, Noor Mansour
Journal: International Journal of Surgery (2020)
144P Analysis of genomic alterations detected by next-generation sequencing-based tissue and circulating tumour DNA assays in Mexican patients with diverse type of malignant tumours
Authors: I.R.R. Gonzalez Espinoza, N. Cortés Escobar, J.C. Garibay Díaz, R. Ibarra Fernández, S. Sánchez Sosa, A. Gozalishvili Boncheva, E. Acosta Ponce de León, M.D.J. González Blanco, C. Aguilar Jímenez, E. Miguel Cruz, M. Sabaté Fernández, J.C. García Reyna, A. Domínguez Peregrina, F.J. Ceja Utrera, D. Arizpe Bravo, M. Lujano de los Santos, L. Cervantes Gómez, L. Perez Mena, C.Á. Sorroza López, J.M. Aguilar Priego
Journal: Annals of Oncology (2020)
1406P External quality assessment of immunohistochemistry, in-situ hybridization and RNA/DNA sequencing for ROS1 testing reveals high concordance for all methods
Authors: M. Ball, J. Fassunke, C. Heydt, J. Fischer, S. Schallenberg, K. Jöhrens, S. Merkelbach-Bruse
Journal: Annals of Oncology (2020)
Electroactive material-based biosensors for detection and drug delivery
Authors: Dinorath Olvera, Michael G. Monaghan
Journal: Advanced Drug Delivery Reviews (2020)

Electroactive materials are employed at the interface of biology and electronics due to their advantageous intrinsic properties as soft organic electronics. We examine the most recent literature of electroactive material-based biosensors and their emerging role as theranostic devices for the delivery of therapeutic agents. We consider electroactive materials through the lens of smart drug delivery systems as materials that enable the release of therapeutic cargo in response to specific physiological and external stimuli and discuss the way these mechanisms are integrated into medical devices with examples of the latest advances. Studies that harness features unique to conductive polymers are emphasized; lastly, we highlight new perspectives and future research direction for this emerging technology and the challenges that remain to overcome.
A Young Patient With Chest Pain
Authors: R. Gunaseelan, M. Sasikumar, N. Balamurugan
Journal: Circulation (2020)

ECG CHALLENGEA 33-year-old man presented to our emergency department with complaints of chest pain for 4 hours.On arrival at our emergency department, the patient was hemodynamically stable.The patient did not have any comorbidities.He was a chronic smoker for 8 years.He denied any cardiac problems in the past.A 12-lead ECG was done, which is shown in Figure 1.What is the diagnosis of this ECG?Please turn the page to read the diagnosis.
1389P IFCT-1602 CHIVA2 phase II trial: Nivolumab in previously treated HIV-patients with advanced non-small cell lung cancer (NSCLC)
Authors: A. Lavole, J. Mazieres, S. Schneider, S. Brosseau, L.M. Kiakouama, L. Greillier, A. Guihot, B. Abbar, M. Baron, A. Makinson, A. Langlais, F. Morin, J-P. Spano, J. Cadranel
Journal: Annals of Oncology (2020)
1454P PARAFIRIGAST: Paclitaxel/ramucirumab versus FOLFIRI as second line chemotherapy of metastatic gastric cancer: An AGEO multicenter comparative study with a propensity score analysis
Authors: J. Wasselin, J. Vivier-Chicoteau, A. Pozet, C. Toullec, S. Racine Doat, C. Smolenschi, A. Turpin, B. De Rauglaudre, D. Sefrioui, O. Bouche, A. Zaanan, M. Kroemer, A. Pellat, A.L. Bignon Bretagne, C. Vitellius, J. Lavole, G. Goujon, Y. Touchefeu, D. Tougeron, V. Hautefeuille
Journal: Annals of Oncology (2020)
654P Real-world treatment (Tx) patterns in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair mutations (HRRm+)
Authors: N. Shore, R. Ionescu-Ittu, F. Laliberté, L. Yang, A. Gayle, S. Payne, M. Mahendran, S. Amin, D. Lejeune, J.E. Burgents, M.S. Duh, L. Yu, S. Ghate
Journal: Annals of Oncology (2020)
Sensory Glia Detect Repulsive Odorants and Drive Olfactory Adaptation
Authors: Duo Duan, Hu Zhang, Xiaomin Yue, Yuedan Fan, Yadan Xue, Jiajie Shao, Gang Ding, Du Chen, Shitian Li, Hankui Cheng, Xiaoyan Zhang, Wenjuan Zou, Jia Liu, Jian Zhao, Linmei Wang, Bingzhen Zhao, Zhiping Wang, Suhong Xu, Quan Wen, Jie Liu, Shumin Duan, Lijun Kang
Journal: Neuron (2020)
232P Safety of fertility treatments in breast cancer survivors
Authors: M. Condorelli, M. De Vos, S. Lie Fong, C. Autin, A. Delvigne, F. Vanden Meerschaut, C. Wyns, R. Imbert, C. Cheruy, J. Bouziotis, M. Lambertini, I. Demeestere
Journal: Annals of Oncology (2020)
Abstract PO-015: Differences in level-of-service for telehealth visits as compared to in-office visits for cancer and hematology patients seen in practices within the ASCO PracticeNET learning network
Authors: Brian Bourbeau, Mou Guharoy, Stephen Grubbs, Elizabeth Garrett-Mayer, Kevin Olson, Richard L. Schilsky
Journal: Clinical Cancer Research (2020)

Abstract Introduction: In response to the need for social distancing and infection prevention during the COVID-19 pandemic, there has been increased use of telehealth services to manage cancer and hematology patients. Throughout March and April of 2020, the Medicare and Medicaid programs expanded coverage of telehealth services, allowing cancer and hematology patients to receive certain telehealth services from their home during the public health emergency. We analyzed data from ASCO’s PracticeNET learning network to examine the reported level-of-service for telehealth services compared to standard in-office visits. Methods: 20 practices submitted their billing data for analysis; practices were located in 14 states and ranged in size from 2 to 29 hematologists/oncologists. We analyzed a total of 33,435 established patient evaluation and management visits performed by hematologists/oncologists from March 15 to April 18, 2020. 3,062 (9.1%) visits were performed via telehealth and 30,373 were performed in a physician office or outpatient hospital department. The level-of-service of each visit was identified through the reported Current Procedure Terminology (CPT) code, where levels 1-5 correspond to CPT codes 99211-99215, respectively, and level 5 represents the highest complexity visit. Telehealth visits were identified through use of the modifiers 95, GQ, and GT, as appended to the applicable CPT code. Results: The level-of-service distribution for telehealth-based visits was level 1 (1%), level 2 (4%), level 3 (35%), level 4 (50%), and level 5 (11%). This contrasted with in-office visits: level 1 (3%), level 2 (2%), level 3 (27%), level 4 (51%), and level 5 (18%). Differences were greatest in level 3 visits (35% vs. 27%) and level 5 visits (11% vs. 18%). Differences in level-of-service persisted when exploring various disease cohorts, including patients with solid neoplasms, blood neoplasms, benign hematology disorders, and circulatory disorders. Conclusions: Analysis of established patient visits showed that telehealth visits were reported at lower level-of-service as compared to in-office visits. This finding may be related to directing straightforward visits to be performed via telehealth or due to limitations in using telehealth by patients with complex medical problems. Citation Format: Brian Bourbeau, Mou Guharoy, Stephen Grubbs, Elizabeth Garrett-Mayer, Kevin Olson, Richard L. Schilsky. Differences in level-of-service for telehealth visits as compared to in-office visits for cancer and hematology patients seen in practices within the ASCO PracticeNET learning network [abstract]. In: Proceedings of the AACR Virtual Meeting: COVID-19 and Cancer; 2020 Jul 20-22. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(18_Suppl):Abstract nr PO-015.
The role of TASL in the pathogenesis of SLE: X marks the spot
Authors: David S Pisetsky
Journal: Annals of the Rheumatic Diseases (2020)

In a seminal paper published in Nature , Heinz et al provide important new information on the gene product of CXorf21 , an X-linked gene associated with systemic lupus erythematosus (SLE).1 Using an impressive array of molecular techniques, these investigators demonstrated that the protein encoded by a gene originally known as CXorf21 interacts with SLC15A4, an amino acid transporter in the endolysosomal compartment; the gene for SLC15A4 has also been genetically associated with SLE. While the role of CXorf21 in SLE had been investigated for many years, the function of its protein product was a mystery until Heinz et al identified it as an adaptor in TLR signalling. The name for this protein is now ‘TLR adaptor interacting with endolysosomal SLC15A4’ or TASL; the gene is designated as TASL (CXorf21 ).

As the studies in THP1 and other human cells in the Nature paper illustrate, TASL is important for the recruitment and activation of the transcription factor IRF5 in downstream signalling by TLR 7, 8 and 9; as such, TASL has analogy with adaptor proteins like STING, MAVS and TRIF. These findings are relevant to the pathogenesis of SLE since, in this disease, DNA and RNA in the form of immune complexes can enter cells of the innate immune system to induce responses by TLR 7, 8 and 9 in the endosomes; the production of interferon and other proinflammatory cytokines is an outcome of this pathway. Interestingly, in its regulation of gene expression, TASL affects the IRF pathway but does not affect NF-κB or MAPK signalling.1 This pattern points to a unique role of TASL in the activation of innate immunity by the endosomal TLRs (figure 1).



Figure 1 
The role of TASL in TLR signalling. As the schematic indicates, TASL plays a key role in the activation of …
Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial
Authors: Andrew Kneebone, Carol Fraser-Browne, Gillian M Duchesne, Richard Fisher, Mark Frydenberg, Alan Herschtal, Scott G Williams, Chris Brown, Warick Delprado, Annette Haworth, David J Joseph, Jarad M Martin, John H L Matthews, Jeremy L Millar, Mark Sidhom, Nigel Spry, Colin I Tang, Sandra Turner, Kirsty L Wiltshire, Henry H Woo, Ian D Davis, Tee S Lim, Maria Pearse
Journal: The Lancet Oncology (2020)
109P Subpopulations of peripheral blood lymphocytes and response to immunotherapy across cancer-types
Authors: J. Garcia-Corbacho, E.A. Gonzalez-Navarro, I. Victoria Ruiz, A. Arrufat, D. Moreno Fernández, L. Heredia, I. Ortiz de Landázuri, N. Vinolas Segarra, B. Mellado, T. Sauri, J. Maurel, L. Gaba, L. Pare, E. Sanfeliu, N. Baste, M.J. Vidal Losada, A.M. Arance Fernandez, N. Reguart, A. Prat, M. Juan
Journal: Annals of Oncology (2020)
Qa-2–Dependent Selection of Cd8<b>α/α</b> T Cell Receptor <b>α/β</b>1 Cells in Murine Intestinal Intraepithelial Lymphocytes
Authors: Gobardhan Das, Dina S. Gould, Mathew M. Augustine, Gladis Fragoso, Edda Sciutto, Iwona Stroynowski, Luc Van Kaer, Danny J. Schust, Hidde Ploegh, Charles A. Janeway
Journal: The Journal of Experimental Medicine (2001)